site:www.thepharmaletter.com - 搜索图片

700 x 466 · jpeg
www.thepharmaletter.com
BridgeBio launches another new company, GondolaBio | Biotechnolog…
700 x 466 · jpeg
www.thepharmaletter.com
Data show diabetes delayed by tirzepatide treatment | Pharmaceutica…
700 x 466 · jpeg
www.thepharmaletter.com
EC approves Astellas’ Padcev for added indication | Pharmaceutical ...
700 x 466 · jpeg
www.thepharmaletter.com
Gavi and the UK can turn a new page together | Pharmaceutical | The ...

700 x 466 · jpeg
www.thepharmaletter.com
Boost to fertility offered by new kind of treatment | Pharmaceutical ...
700 x 467 · jpeg
www.thepharmaletter.com
Gilead CMO Merdad Parsey to leave in early 2025 | Biotechnology | The ...
700 x 466 · jpeg
www.thepharmaletter.com
Broader label for GSK's Arexvy after new European nod | Pharmaceutical ...
700 x 466 · jpeg
www.thepharmaletter.com
Arrowhead to advance obesity drug candidates into clinic ...

700 x 466 · jpeg
www.thepharmaletter.com
Strategic overhaul at Acelyrin after late-stage success | Biotechnology ...
700 x 466 · jpeg
www.thepharmaletter.com
Court battles continue as Regeneron staves off Eylea copycats ...
700 x 466 · jpeg
www.thepharmaletter.com
New approach to diabetes is effective in mid-stage trial ...
700 x 466 · jpeg
www.thepharmaletter.com
Positive Phase III results for Novartis twice-yearly Leqvio ...

700 x 466 · jpeg
www.thepharmaletter.com
FDA approves Lazcluze with Rybrevant for NSCLC | Biotechnology | The ...
700 x 466 · jpeg
www.thepharmaletter.com
MHRA approves GLP–1 receptor agonist Wegovy for new use ...
700 x 466 · jpeg
www.thepharmaletter.com
Seattle start-up ZipBio to use AI for gene therapies | Biotechnology ...
700 x 466 · jpeg
www.thepharmaletter.com
Roche gains EC approval for Vabysmo as RVO treatment | Biotechnology ...

700 x 466 · jpeg
www.thepharmaletter.com
US and EU regulatory progress for Enhertu in breast cancer ...
700 x 466 · png
www.thepharmaletter.com
FTC supports FDA guidance on interchangeable biosimilar drugs ...
700 x 466 · jpeg
www.thepharmaletter.com
Pantherx Rare selected for distribution of Torpenz | Pharmaceutical ...
700 x 466 · jpeg
www.thepharmaletter.com
FDA releases FY23 GDUFA Science and Research Report | The Pharmale…

700 x 466 · jpeg
www.thepharmaletter.com
UK launches £400 million initiative to boost clinical trials ...
700 x 466 · jpeg
www.thepharmaletter.com
AAVantgarde Bio appoints new chief medical officer | Biotechnology ...
700 x 466 · jpeg
www.thepharmaletter.com
Ipsen and Day One in ex-US tovorafenib deal for most common ch…
748 x 498 · jpeg
www.thepharmaletter.com
Patient-focused drug development: is behavioural science the answer to ...

700 x 467 · jpeg
www.thepharmaletter.com
Moderna's rare disease candidate selected for US FDA's START progra…
700 x 466 · jpeg
www.thepharmaletter.com
New asthma indication approved by FDA for Trelegy Ellipta | The ...
700 x 466 · jpeg
www.thepharmaletter.com
Merck & Co sees value in novel prostate cancer drug | Pharmaceutic…
700 x 466 · jpeg
www.thepharmaletter.com
Strong Phase III data for new dual action GLP-1 candidate ...

700 x 466 · jpeg
www.thepharmaletter.com
OcuMension buys Chinese rights to Alcon dry eye drugs | Pharmaceutica…
700 x 466 · jpeg
www.thepharmaletter.com
Positive Phase III data on AstraZeneca and Daiichi Sankyo’s datopotamab ...
700 x 466 · jpeg
www.thepharmaletter.com
Blenrep back from the brink with more positive Phase III data ...
700 x 466 · jpeg
www.thepharmaletter.com
Genor Biopharma announces merger with Edding in Hong Kong ...

700 x 466 · jpeg
www.thepharmaletter.com
Mixed but encouraging results for Lilly's donanemab in Alzheimer's ...
700 x 466 · jpeg
www.thepharmaletter.com
Biogen’s aducanumab aims to be first DMT approved in 17 years for Alzh ...
700 x 466 · jpeg
www.thepharmaletter.com
Chugai debuts its new NMOSD drug Enspryng in Japan | The Pharmaletter

某些结果已被隐藏，因为你可能无法访问这些结果。显示无法访问的结果